Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 3
1982 1
1984 2
1987 2
1988 3
1989 5
1990 4
1991 4
1992 2
1993 5
1994 4
1995 5
1996 4
1997 6
1998 2
1999 2
2000 3
2001 3
2002 8
2003 4
2004 4
2005 6
2006 7
2007 6
2008 1
2009 4
2010 11
2011 5
2012 13
2013 8
2014 5
2015 11
2016 15
2017 10
2018 12
2019 6
2020 16
2021 15
2022 15
2023 16
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

239 results

Results by year

Filters applied: . Clear all
Page 1
Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments.
Olivotto I, Udelson JE, Pieroni M, Rapezzi C. Olivotto I, et al. Eur Heart J. 2023 Feb 21;44(8):656-667. doi: 10.1093/eurheartj/ehac764. Eur Heart J. 2023. PMID: 36582184 Review.
The present review addressed existing and developing therapies for genetic causes of HFpEF, including hypertrophic cardiomyopathy, cardiac amyloidosis, and storage diseases, discussing their potential impact on management and their broader implications for our under …
The present review addressed existing and developing therapies for genetic causes of HFpEF, including hypertrophic cardiomyopathy …
Causes of sudden cardiac death in young athletes and non-athletes: systematic review and meta-analysis: Sudden cardiac death in the young.
D'Ascenzi F, Valentini F, Pistoresi S, Frascaro F, Piu P, Cavigli L, Valente S, Focardi M, Cameli M, Bonifazi M, Metra M, Mondillo S. D'Ascenzi F, et al. Trends Cardiovasc Med. 2022 Jul;32(5):299-308. doi: 10.1016/j.tcm.2021.06.001. Epub 2021 Jun 22. Trends Cardiovasc Med. 2022. PMID: 34166791 Review.
Comparing the causes of SCD between athletes and non-athletes, non-ischemic left ventricular scar (NILVS) (5.1% vs. 1.1%, p=0.01) was more frequent in the former, while coronary artery disease (CAD) (19.6% vs. 9.1%, p=0.009), arrhythmogenic cardiomyopathy (ACM) (11.5% vs. …
Comparing the causes of SCD between athletes and non-athletes, non-ischemic left ventricular scar (NILVS) (5.1% vs. 1.1%, p=0.01) was more f …
Current therapies for hypertrophic cardiomyopathy: a systematic review and meta-analysis of the literature.
Bayonas-Ruiz A, Muñoz-Franco FM, Sabater-Molina M, Oliva-Sandoval MJ, Gimeno JR, Bonacasa B. Bayonas-Ruiz A, et al. ESC Heart Fail. 2023 Feb;10(1):8-23. doi: 10.1002/ehf2.14142. Epub 2022 Oct 1. ESC Heart Fail. 2023. PMID: 36181355 Free PMC article. Review.
AIMS: The aim of this study was to synthesize the evidence on the effect of the current therapies over the pathophysiological and clinical characteristics of patients with hypertrophic cardiomyopathy (HCM). METHODS AND RESULTS: A systematic review and meta-analysis …
AIMS: The aim of this study was to synthesize the evidence on the effect of the current therapies over the pathophysiological and clinical c …
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know.
Marano P, Wei J, Merz CNB. Marano P, et al. Curr Atheroscler Rep. 2023 Aug;25(8):435-446. doi: 10.1007/s11883-023-01116-z. Epub 2023 Jun 20. Curr Atheroscler Rep. 2023. PMID: 37338666 Free PMC article. Review.
It is also associated with adverse outcomes in patient populations including hypertrophic cardiomyopathy, dilated cardiomyopathy, and acute coronary syndromes. ...
It is also associated with adverse outcomes in patient populations including hypertrophic cardiomyopathy, dilated cardiomyo …
The evolving paradigm and current perception of hypertrophic cardiomyopathy: Implications for management.
Del Franco A, Menale S, Chiti C, Biagioni G, Tomberli A, Zampieri M, Olivotto I. Del Franco A, et al. Prog Cardiovasc Dis. 2023 Sep-Oct;80:8-13. doi: 10.1016/j.pcad.2023.08.002. Epub 2023 Aug 10. Prog Cardiovasc Dis. 2023. PMID: 37572782 Review.
Recent evidence from imaging and genetic screening studies has clearly shown that hypertrophic cardiomyopathy (HCM) is more common than initially perceived, emphasizing the need to reassess its associated clinical and social burden. ...
Recent evidence from imaging and genetic screening studies has clearly shown that hypertrophic cardiomyopathy (HCM) is more co …
Hypertrophic Cardiomyopathy: Genetic Foundations, Outcomes, Interconnections, and Their Modifiers.
Glavaški M, Velicki L, Vučinić N. Glavaški M, et al. Medicina (Kaunas). 2023 Aug 4;59(8):1424. doi: 10.3390/medicina59081424. Medicina (Kaunas). 2023. PMID: 37629714 Free PMC article. Review.
Hypertrophic cardiomyopathy (HCM) is the most prevalent heritable cardiomyopathy. ...
Hypertrophic cardiomyopathy (HCM) is the most prevalent heritable cardiomyopathy. ...
Barth syndrome.
Clarke SL, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, Clayton N, Martin RP, Tsai-Goodman B, Garratt V, Ashworth M, Bowen VM, McCurdy KR, Damin MK, Spencer CT, Toth MJ, Kelley RI, Steward CG. Clarke SL, et al. Orphanet J Rare Dis. 2013 Feb 12;8:23. doi: 10.1186/1750-1172-8-23. Orphanet J Rare Dis. 2013. PMID: 23398819 Free PMC article. Review.
First described in 1983, Barth syndrome (BTHS) is widely regarded as a rare X-linked genetic disease characterised by cardiomyopathy (CM), skeletal myopathy, growth delay, neutropenia and increased urinary excretion of 3-methylglutaconic acid (3-MGCA). ...Clinical features …
First described in 1983, Barth syndrome (BTHS) is widely regarded as a rare X-linked genetic disease characterised by cardiomyopathy …
Exercise and hypertrophic cardiomyopathy: Two incompatible entities?
Basu J, Malhotra A, Papadakis M. Basu J, et al. Clin Cardiol. 2020 Aug;43(8):889-896. doi: 10.1002/clc.23343. Epub 2020 Feb 12. Clin Cardiol. 2020. PMID: 32048747 Free PMC article. Review.
A greater understanding of the pathogenic mechanisms underpinning hypertrophic cardiomyopathy (HCM) has translated to improved medical care and better survival of affected individuals. ...
A greater understanding of the pathogenic mechanisms underpinning hypertrophic cardiomyopathy (HCM) has translated to improved …
Evaluation of Hypertrophic Cardiomyopathy: Newer Echo and MRI Approaches.
Habib M, Hoss S, Rakowski H. Habib M, et al. Curr Cardiol Rep. 2019 Jun 26;21(8):75. doi: 10.1007/s11886-019-1173-1. Curr Cardiol Rep. 2019. PMID: 31243594 Review.
PURPOSE OF REVIEW: This review discusses the basic and evolving echocardiographic and cardiac magnetic resonance (CMR) approaches in the diagnosis and management of patients with hypertrophic cardiomyopathy (HCM). RECENT FINDINGS: Newer imaging technologies and tech …
PURPOSE OF REVIEW: This review discusses the basic and evolving echocardiographic and cardiac magnetic resonance (CMR) approaches in the dia …
239 results